552-01-008 / 552-01-008 ISMRM Abstract

Longitudinal metabolic and microstructural changes in low-grade gliomas treated with vorasidenib

Primary: Neuro - Tumors

Secondary: Contrast Mechanisms - Spectroscopy

552-01-008 · Novel Approaches to Spectroscopy · Wednesday, 13 May, 8:20 AM–9:56 AM · Power Pitch Theatre 2

Keywords: Treatment Response Spectroscopy Glioma Diffusion-weighted MRI Vorasidenib

Accepted

Capucine Cadin ¹, Lucia Nichelli^1,2, Malgorzata Marjanska³, Mélanie Didier¹, Filip Szczepankiewicz⁴, Markus Nilsson⁴, Alberto Picca^1,2, Caroline Dehais^1,2, Bertrand Mathon^1,2, Stéphane Lehéricy^1,2, Franck Bielle^1,2, Marc Sanson^1,2, Mehdi Touat^1,2, Francesca Branzoli¹

¹Paris Brain Institute - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne University, Paris, France

²Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles-Foix, Paris, France

³Center for Magnetic Resonance Research, Dept. of Radiology, University of Minnesota, Minneapolis, United States of America

⁴Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, Sweden

Presenting Author: Capucine Cadin

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. I. K. Mellinghoff et al., « Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial », Nat Med, vol. 29, no 3, p. 615‑622, mars 2023, doi: 10.1038/s41591-022-02141-2. [doi]

2. A. L. Di Stefano et al., « In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of IDH-Mutant Diffuse Gliomas: The IDASPE Prospective Study », Neurology, vol. 100, no 1, p. e94‑e106, janv. 2023, doi: 10.1212/WNL.0000000000201137. [doi]

3. A. R. Molloy et al., « MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma », Theranostics, vol. 10, no 19, p. 8757‑8770, 2020, doi: 10.7150/thno.47317. [doi]

4. O. C. Andronesi et al., « Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate », Nat Commun, vol. 9, no 1, p. 1474, avr. 2018, doi: 10.1038/s41467-018-03905-6. [doi]

5. F. Szczepankiewicz et al., « The link between diffusion MRI and tumor heterogeneity: Mapping cell eccentricity and density by diffusional variance decomposition (DIVIDE) », Neuroimage, vol. 142, p. 522‑532, nov. 2016, doi: 10.1016/j.neuroimage.2016.07.038. [doi]

6. M. Nilsson et al., « Tensor‐valued diffusion MRI in under 3 minutes: an initial survey of microscopic anisotropy and tissue heterogeneity in intracranial tumors », Magn Reson Med, vol. 83, no 2, p. 608‑620, févr. 2020, doi: 10.1002/mrm.27959. [doi]

7. I. K. Mellinghoff et al., « Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma », N Engl J Med, vol. 389, no 7, p. 589‑601, août 2023, doi: 10.1056/NEJMoa2304194. [doi]

8. M. Mescher, H. Merkle, J. Kirsch, M. Garwood, et R. Gruetter, « Simultaneous in vivo spectral editing and water suppression », NMR Biomed, vol. 11, no 6, p. 266‑272, oct. 1998, doi: 10.1002/(sici)1099-1492(199810)11:6<266::aid-nbm530>3.0.co;2-j. [doi]

9. I. Tkác, Z. Starcuk, I. Y. Choi, et R. Gruetter, « In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time », Magn Reson Med, vol. 41, no 4, p. 649‑656, avr. 1999, doi: 10.1002/(sici)1522-2594(199904)41:4<649::aid-mrm2>3.0.co;2-g. [doi]

10. S. W. Provencher, « Estimation of metabolite concentrations from localized in vivo proton NMR spectra », Magn Reson Med, vol. 30, no 6, p. 672‑679, déc. 1993, doi: 10.1002/mrm.1910300604. [doi]

11. F. Szczepankiewicz, J. Sjölund, F. Ståhlberg, J. Lätt, et M. Nilsson, « Tensor-valued diffusion encoding for diffusional variance decomposition (DIVIDE): Technical feasibility in clinical MRI systems », PLoS ONE, vol. 14, no 3, p. e0214238, mars 2019, doi: 10.1371/journal.pone.0214238. [doi]

12. Z. J. Reitman et al., « Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome », Proc Natl Acad Sci U S A, vol. 108, no 8, p. 3270‑3275, févr. 2011, doi: 10.1073/pnas.1019393108. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/552-01-008